Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience (NASDAQ: TWST) has announced it will release its fiscal 2025 first quarter financial results for the period ended December 31, 2024, before market opening on February 3, 2025. The company will host a conference call and live audio webcast for analysts and investors at 8:00 AM Eastern Time on the same day.
Participants interested in joining via telephone must pre-register through the company's Investor Relations website. The financial results press release will be available on the company's website in the Investor Relations section. A webcast replay will be accessible for two weeks following the call.
Twist Bioscience (NASDAQ: TWST), a mid-cap life sciences company, has announced that CEO and co-founder Emily M. Leproust, Ph.D. will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 5:15 p.m. Pacific Time in San Francisco, California.
The event will be accessible via webcast through the company's investor relations website's 'Investor Calendar' section. Following the live presentation, a replay will remain available for 30 days.
Twist Bioscience (NASDAQ: TWST) announced its financial results for Q4 and full year fiscal 2024 ended September 30, 2024. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Participants can access detailed earnings reports and investor presentations through the company's website. Those joining via telephone must register in advance to receive dial-in information.
Twist Bioscience (NASDAQ: TWST), a synthetic DNA manufacturer, announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO and co-founder Emily M. Leproust, Ph.D., along with CFO Adam Laponis, will engage in a fireside chat on December 3, 2024, at 10:00 a.m. Eastern Time in Coral Gables, Florida. The event will be accessible via live webcast through the company's investor relations website, with a replay available for 30 days after the presentation.
Twist Bioscience (NASDAQ: TWST) has announced new equity awards as employment inducements under Nasdaq Rule 5635(c)(4). The company granted 110,300 restricted stock units (RSUs) to 43 new employees and up to 37,500 performance stock units (PSUs) to VP Colby Souders. The RSUs vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs vest based on performance metrics for FY2024-2026, with potential earnings of 80%-150% of target, subject to continued employment.
Twist Bioscience (NASDAQ: TWST) has launched the FlexPrep™ Ultra-High Throughput Library Preparation Kit, featuring proprietary Normalization by Ligation™ technology. The kit enables processing of thousands of samples at low cost, eliminating the need for upfront sample quantitation and allowing early sample pooling. Researchers can run up to 1,152 samples in a single 96-well plate, reducing consumables by 12x and pipette tips usage from 17,000 to under 4,000. The company is collaborating with Gencove to provide genomic analysis software, offering an end-to-end workflow solution for agricultural and population genomics applications.
Twist Bioscience (NASDAQ: TWST) has announced it will release its fiscal 2024 fourth quarter and full year financial results on November 18, 2024, before market opening. The company will host a conference call and live audio webcast for analysts and investors at 8:00 AM Eastern Time. Participants interested in joining via telephone must register through the company's Investor Relations website. A webcast replay will be available for two weeks following the call.
Twist Bioscience (NASDAQ: TWST) has entered into a royalty purchase agreement with XOMA Royalty (NASDAQ: XOMA). Under the agreement, XOMA Royalty will provide Twist with an upfront payment of $15 million in exchange for the right to receive half of the future potential milestone and royalty payments from Twist's existing antibody discovery and biopharma services collaborations.
Twist will retain all upfront, service, and other revenue from these collaborations, as well as full rights to future biopharma collaborations with milestone and royalty terms. The agreement does not apply to synbio, NGS, or data storage revenue. This deal aims to provide Twist with immediate capital to support continued innovation and profitable growth across the company.
Twist Bioscience (NASDAQ: TWST) has appointed Mike Fero, Ph.D., as Chief Information Officer. Dr. Fero brings over 30 years of experience in startups, commercial software development, biology and physics research, and deep-tech businesses. His background includes building scalable enterprise software platforms and understanding systems biology and artificial intelligence. Dr. Fero was previously a Twist customer, giving him unique insights into the company's mission.
Before joining Twist, Dr. Fero co-founded and served as CEO of TeselaGen Biotechnology for a decade, developing an enterprise software platform for DNA design and management. He has also held positions at Stanford University, Neomorphic, HyperParallel, and MIT. Dr. Fero holds a Ph.D. in Physics and a B.A. in Math and Physics from UC Irvine.
Twist Bioscience (NASDAQ: TWST) has achieved LEED certification for its Wilsonville, OR facility, demonstrating its commitment to sustainability in operations and maintenance. The certification, awarded by the U.S. Green Building Council, recognizes the facility's adherence to LEED v4.1 Operations + Maintenance standards.
CEO Emily M. Leproust emphasized that this achievement aligns with Twist's mission to improve health and sustainability. The company previously quantified the carbon footprint of gene production using their platform, showing significant environmental benefits compared to traditional methods. This LEED certification further solidifies Twist's commitment to providing customers with DNA produced in a sustainable facility using fewer chemical reagents.